PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

NCT06245889 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Pembrolizumab
DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Olaparib
DRUG: Capecitabine

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]